Michael Gibney
Senior Editor & WriterMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
33 articles by Michael Gibney
-
Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut
Oct. 3, 2022 -
How do Biogen-Eisai’s two Alzheimer’s drugs stack up?
Sept. 30, 2022 -
From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge
Sept. 12, 2022 -
Entrepreneurs: Armon Sharei
Sept. 6, 2022 -
Entrepreneurs: David Katz
Sept. 6, 2022 -
Disrupters: Julie Kim
Sept. 6, 2022 -
Entrepreneurs: Kuldeep Singh Rajput
Sept. 6, 2022 -
Disrupters: Sally Allain
Sept. 6, 2022 -
First 90 Days: Adaptive Biotech’s Tycho Peterson
Sept. 1, 2022 -
The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact
Aug. 29, 2022 -
Patents, pandemics and pricing: a peek at the top drug from every big pharma
Aug. 22, 2022 -
Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics
Aug. 11, 2022 -
As pharma M&A ramps up, U.S. execs are bullish on more deals
Aug. 11, 2022 -
Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?
Aug. 4, 2022 -
What’s next for Biogen? Here’s what executives are saying
July 27, 2022 -
A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets
July 25, 2022 -
With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about
July 21, 2022 -
Biotech R&D spending has skyrocketed, and so have opportunities for savings
July 19, 2022 -
Why a 'fundamental shift' in regulatory submissions is on the way
July 11, 2022 -
The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman
June 29, 2022 -
#DIA2022: How the industry's top regulator views the future of healthcare
June 21, 2022 -
First 90 Days: Editas Medicine's Gilmore O'Neill
June 13, 2022 -
As cancer innovations thrive, patient access is the next piece of the puzzle
June 8, 2022 -
How to build a cancer pipeline: Big Pharma oncology heads on driving science forward
June 6, 2022 -
PBMs under fire for drug prices defend their worth
May 26, 2022